publications
- Badarni, M., Prasad, M., Balaban, N., Zorea, J., Yegodayev, K. M., Ben-Zion, J.,& Elkabets, M. (2019). Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI insight, 4(8).
- Ghosh, S., Prasad, M., Kundu, K., Cohen, L., Yegodayev, K. M., Zorea, J., & Mizrachi, A. (2019). Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy. Frontiers in oncology, 9.
- Novoplansky, O., Fury, M., Prasad, M., Yegodayev, K., Zorea, J., Cohen, L., & Joshua, B. Z. (2019). MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International journal of cancer.
- Dym, T. Kaisman-Elbaz, M. Atar-Vardi, V. Merkin, I. Melamed, A. Cohen, V. Borodetsky, I. Shelef. Poster, Israeli Neurosurgery Society Annual meeting, Yesud HaMa’ala-Israel, 10-12 May 2017. Retrospective evaluation of Glioblastoma contact with sub-ventricular zone and its associated influence on patients’ survival.
- Merkin, T. Kaisman-Elbaz, M. Atar-Vardi, I. Melamed. Poster, Israeli Neurosurgery Society Annual meeting, Yesud HaMa’ala-Israel, 10-12 May 2017, Image guided frameless stereotactic needle brain biopsies – a decade of experience in Soroka University Medical Center.
- Kaisman-Elbaz T, Dym L, Sigal-Batikoff I, Atar-Vardi M, Kantor I, Gidon M, Merkin V, Melamed I, Cohen. Oral presentation, Israeli Neurosurgery Society Annual meeting, 31 March 2016. Retrospective and prospective study of Glioblastoma patients’ survival in Soroka University Medical Center and the establishment of Glioblastoma research lab.
- Ariel Noy, Lianne Dym, Maya Atar-Vardi, Sivan Turiel, Noa Rotem-Dai, Vladimir Merkin, Israel Melamed, Avi Cohen, Konstantin Lavrenkov, Victor Diumin, Tehila Kaisman-Elbaz. Initial Steps towards Establishment of Multifactorial Prognostic Model of Soroka University Medical Center Glioblastoma Patients’. Galilee, Israel 2018.
- Snir Haddad, Zohar Hovev, Maya Atar-Vardi, Sivan Turiel, Noa Rotem-Dai, Vladimir Merkin, Israel Melamed, Avi Cohen, Konstantin Lavrenkov, Victor Diumin, Tehila Kaisman-Elbaz. Matrix Metalloproteinases (MMPs) Expression Level and its Correlation with Malignant Brain Tumors Invasiveness and Patients’ Survival. Galilee, Israel 2018. This study was conducted as part of the requirements for Ms. Zohar Hovev and Ms. Snir Haddad M.D. degree from The Joyce & Irving Goldman Medical School, Faculty of health sciences, Ben-Gurion University of the Negev.
- Snir Haddad, Yael Eskira, Zohar Hovev, Maya Atar-Vardi, Sivan Turiel,Noa Rotem-Dai, Vladimir Merkin, Israel Melamed, Konstantin Lavrenkov, Tehila Kaisman-Elbaz. Matrix Metalloproteinase 9 Expression Level and its Correlation With Glioblastoma Invasiveness and Patients’ Survival. Galilee, Israel 2019. This study was conducted as part of the requirements for Ms. Snir Haddad M.D. degree from The Joyce & Irving Goldman Medical School, Faculty of health sciences, Ben-Gurion University of the Negev.
- AP-1 regulates AXL expression and induces resistance to PI3Ka inhibition in esophageal and head and neck cancer” – EAI 2018, Jerusalem, Israel, Oct 2018 – Confirmed- selected speak
- AP-1 regulates AXL expression and induces resistance to PI3Ka inhibition in esophageal and head and neck cancer” – EMBO 2018, Cavtat, Croatia, Sep 2018 – Flash talk
- JNK/AP-1 axis regulates AXL expression and determines the efficacy of PI3Ka therapy in head and neck cancer – Parnace meeting, Kyiv, Ukraine Sept 2018 –Invited speak
- JNK/AP-1 axis regulates AXL expression and determines the efficacy of PI3Ka therapy in head and neck cancer – Sixth ISF-Broad meeting, Boston, July MA 2018 – Invited speaker
- Diversity of transcriptional factor machinery the drive resistance to anti-cancer drugs in head and neck cancer – King’s College London March 2018 – Invited speaker
- MET drive resistance to cetuximab in head and neck cancer– 9th Molecular Immunology & Immunogenetics Congress, London, UK March 2018 – Invited speaker
- “The role of JUN in resistance to PI3Ka in head and neck cancer” – EORTC, Leipzig, Germany Nov 2017 – Invited speaker
- “Drug resistance in cancer: the enemy is in and around the tumor cells.” – Ilanit 2017- Feb 2017, Eilat Israel.
- “BioBanking Head and neck Cancer” – ISHNOS – Goshrim Nov 2016 – Invited speaker
- “Targeted and Immunotherapy in head and neck cancer” – Sorasky Medical Center July 2016 – Invited speaker
- ” AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas”- EMBO, Cravat, Croatia 28th May 2016
Media publications
Previous
Next
publications
Published papers
1. Badarni, M., Prasad, M., Balaban, N., Zorea, J., Yegodayev, K. M., Ben-Zion, J.,& Elkabets, M. (2019). Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI insight, 4(8).
2. Ghosh, S., Prasad, M., Kundu, K., Cohen, L., Yegodayev, KM., Zorea, J., Joshua, BZ., Lasry, B., Dimitstein, O., Bahat-Dinur, A., Mizrachi, A., Lazar, V., Elkabets, M., Porgador A (2019). Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy. Frontiers in oncology, 9.
3. Novoplansky, O., Fury, M., Prasad, M., Yegodayev, K., Zorea, J., Cohen, L., & Joshua, BZ. (2019). MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International journal of cancer.